Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has spread to more than 70 countries worldwide since 2015. Despite active research, there are currently no licensed vaccines or therapeutics. We have previously reported the development of various adenoviral vectored vaccine candidates...

Podrobná bibliografie
Hlavní autoři:	López-Camacho, C, Kim, Y, Abbink, P, Larocca, R, Huiskonen, J, Barouch, D, Reyes-Sandoval, A
Médium:	Journal article
Jazyk:	English
Vydáno:	MDPI 2019

Podobné jednotky

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
Autor: César López-Camacho, a další
Vydáno: (2019-11-01)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
Autor: Moorthy, V, a další
Vydáno: (2003)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
Autor: Alharbi, N
Vydáno: (2014)

Clinical development of Modified Vaccinia virus Ankara vaccines.
Autor: Gilbert, S
Vydáno: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
Autor: Gilbert, S
Vydáno: (2013)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
Autor: McConkey, S, a další
Vydáno: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
Autor: Rosario, M, a další
Vydáno: (2010)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
Autor: Schneider, J, a další
Vydáno: (1998)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
Autor: L. F. Stovba, a další
Vydáno: (2023-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
Autor: Olga Vladimirovna Orlova, a další
Vydáno: (2022-09-01)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
Autor: Nereida Jiménez de Oya, a další
Vydáno: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
Autor: López-Camacho, C, a další
Vydáno: (2020)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
Autor: Alharbi, N, a další
Vydáno: (2015)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
Autor: Naif Khalaf Alharbi, a další
Vydáno: (2015-01-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Autor: Lior Nave, a další
Vydáno: (2023-08-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
Autor: Kaïdre Bendjama, a další
Vydáno: (2017-09-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
Autor: Goepfert P, a další
Vydáno: (2012-09-01)

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial
Autor: Milligan, I, a další
Vydáno: (2016)

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
Autor: Milligan, I, a další
Vydáno: (2016)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
Autor: Mcshane, H, a další
Vydáno: (2001)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
Autor: Behboudi, S, a další
Vydáno: (2004)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
Autor: César López-Camacho, a další
Vydáno: (2020-06-01)

Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
Autor: Valentina Mazzotta, a další
Vydáno: (2024-12-01)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
Autor: Goonetilleke, N, a další
Vydáno: (2003)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
Autor: Mingwang Shen, a další
Vydáno: (2024-10-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
Autor: Gilbert, S, a další
Vydáno: (1999)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
Autor: Juan García-Arriaza, a další
Vydáno: (2021-08-01)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
Autor: Jeffrey R Currier, a další
Vydáno: (2010-11-01)

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
Autor: Sandhya Vasan, a další
Vydáno: (2010-01-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
Autor: Hanke, T, a další
Vydáno: (1998)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
Autor: Howles, S, a další
Vydáno: (2010)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
Autor: Caroline Staib, a další
Vydáno: (2003-04-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
Autor: Volker Sandig, a další
Vydáno: (2013-11-01)

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Autor: Leonie Mayer, a další
Vydáno: (2024-11-01)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
Autor: Flavia Chiuppesi, a další
Vydáno: (2024-02-01)

The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
Autor: Franziska Tanneberger, a další
Vydáno: (2021-10-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
Autor: Harriet L. Robinson, a další
Vydáno: (2018-09-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Autor: David A Garber, a další
Vydáno: (2009-01-01)

Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
Autor: Leonie Mayer, a další
Vydáno: (2024-12-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
Autor: C. Staib, a další
Vydáno: (2000-06-01)